Winton Group LTD Fate Therapeutics Inc Transaction History

Winton Group LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$17.78 - $42.39 $129,794 - $309,447	-7,300 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$29.67 - $60.28 $216,591 - $440,044	7,300 New	7,300 $283,000
Q4 2021 Feb 10, 2022	SELL	$47.84 - $64.34 $171,362 - $230,465	-3,582 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$59.27 - $95.73 $212,305 - $342,904	3,582 New	3,582 $212,000
Q2 2021 Aug 10, 2021	SELL	$67.25 - $92.52 $410,964 - $565,389	-6,111 Closed	0 $0
Q1 2021 Jul 21, 2021	BUY	$72.16 - $117.4 $171,812 - $279,529	2,381 Added 63.83%	6,111 $504,000
Q4 2020 Feb 12, 2021	BUY	$38.09 - $100.95 $142,075 - $376,543	3,730 New	3,730 $339,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $160M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.